Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.57 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.57 |
| ▸ | HPGD | P15428 | 1/20 | 0.57 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | TNFRSF1A | P19438 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30384498 | 1.00 | HTR7 (0.62) | HTR7MAPK1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL3440769 | 1.00 | HTR7 (0.62) | HTR7MAPK1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL30384562 | 0.93 | HTR7 (0.60) | HTR7MAPK1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL13105457 | 0.93 | HTR7 (0.60) | HTR7MAPK1L3MBTL1KDM4ECYP3A4 | |
| SCHEMBL3440503 | 0.90 | MAPK1 (0.71) | HTR7MAPK1L3MBTL1MAPTLMNA | |
| SCHEMBL3440502 | 0.90 | MAPK1 (0.71) | HTR7MAPK1L3MBTL1MAPTLMNA | |
| SCHEMBL25192218 | 0.87 | HTR7 (0.70) | HTR7MAPK1L3MBTL1MAPTLMNA | |
| SCHEMBL31233271 | 0.87 | HTR7 (0.67) | HTR7MAPK1L3MBTL1MAPTLMNA | |
| SCHEMBL25192668 | 0.87 | HTR7 (0.70) | HTR7MAPK1L3MBTL1MAPTLMNA | |
| SCHEMBL31233077 | 0.85 | ABCB1 (0.71) | HTR7MAPK1L3MBTL1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7807712-B2 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2010-10-05 | — | — | US | claimed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | claimed |
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | YEWSAVIN INC (US) | 2026-01-15 | — | — | US | disclosed |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | YewSavin, Inc. (US) | 2025-07-01 | — | — | US | disclosed |
| EP-4429763-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | Yewsavin, Inc. (US) | 2024-09-18 | — | — | EP | disclosed |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-06-22 | — | — | US | disclosed |
| WO-2023086388-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | YewSavin, Inc. (US) | 2023-05-19 | — | — | WO | disclosed |
| US-7807712-B2 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2010-10-05 | — | — | US | disclosed |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | PRATAP RAM | 2006-06-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260014100-A1 | Compositions and Methods for Treating Bleeding and Bleeding Disorders | SERPINC1, F2, F13B | HTR7 1804/4885MAPK1 3352/4885L3MBTL1 3658/4885 |
| US-20230190679-A1 | COMPOSITIONS AND METHODS FOR TREATING BLEEDING AND BLEEDING DISORDERS | SERPINC1, SERPINE1, SERPINH1 | HTR7 2739/4885MAPK1 3412/4885L3MBTL1 2560/4885 |
| US-20060142303-A1 | Oxy substituted chalcones as antihyperglycemic and antidyslipidemic agents | LIPC, CYP46A1, HMGCR | HTR7 2286/4885MAPK1 1830/4885L3MBTL1 2550/4885 |
| US-12343317-B2 | Compositions and methods for treating bleeding and bleeding disorders | SERPINC1, SERPINE1, SERPINH1 | HTR7 2739/4885MAPK1 3412/4885L3MBTL1 2560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.